Resource Summary Report

Generated by RRID on Sep 8, 2026

LNCaP C4-2

RRID:CVCL_4782
Type: Cell Line

Proper Citation

RRID:CVCL_4782

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4782

Proper Citation: RRID:CVCL_4782

Description: Cell line LNCaP C4-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Prostate carcinoma

Defining Citation: PMID:8169003, PMID:15162376, PMID:26499105, PMID:29194687, PMID:35502546

Comments: Characteristics: Exhibits androgen-independent growth associated with skeletal metastasis, produces metastases when injected either subcutaneously or orthotopically in intact or castrated mice., Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LNCaP C4-2

Synonyms: LNCaP-C4-2, LNCaP subline C4-2, C4-2, C42, Sp 2817

Cross References: BTO:BTO_0005672, ATCC:CRL-3314, cancercelllines:CVCL_4782, ChEMBL-Cells:CHEMBL4295439, ChEMBL-Targets:CHEMBL4296460, CLS:305752, Cosmic:1330914, GEO:GSM3145590, GEO:GSM3145694, PubChem_Cell_line:CVCL_4782, Wikidata:Q54902814

ID: CVCL_4782

Hierarchy: cvcl_4783

Record Creation Time: 20220427T220731+0000

Record Last Update: 20260905T181035+0000

Ratings and Alerts

No rating or validation information has been found for LNCaP C4-2.

No alerts have been found for LNCaP C4-2.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 390 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Gordon N, et al. (2026) PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer. Molecular oncology, 20(6), 1626.

Al-Mathkour MM, et al. (2026) The YAP1 and EPHA3 receptor tyrosine kinase axis regulates cellular plasticity and treatment response. Cellular signalling, 141, 112368.

Kim SH, et al. (2026) Synthesis of Bispecific Conjugates by ADP-Ribosyl Cyclases. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(13), e18329.

Zheng W, et al. (2026) hsa-circKLK3-25 promotes epithelial-mesenchymal transition and malignant progression of prostate cancer through the JNK/ERK signaling pathway. American journal of cancer research, 16(3), 1081.

Rodrigues SD, et al. (2026) Suppression of de novo lipogenesis and dietary PUFA supplementation inhibit prostate cancer progression. bioRxiv : the preprint server for biology.

Huang J, et al. (2026) The FOSB-IGFBP5-IGF-1 axis: a novel regulatory pathway that suppresses prostate cancer growth. Cancer gene therapy.

Zhao D, et al. (2026) Lactate derived from cancer-associated fibroblasts promotes alternative splicing and castration resistance in prostate cancer. Science advances, 12(3), eady5324.

Liu S, et al. (2026) Betulinic acid induces lysosome-dependent death in prostate cancer by targeting DDX5. Phytomedicine : international journal of phytotherapy and phytopharmacology, 155, 158143.

Fang B, et al. (2026) EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer. The

Journal of clinical investigation, 136(11).

Luo T, et al. (2026) Butyrylated PGAM5-Triggered and GSH-Responsive Cysteine Polymer Nanoparticles for CBL0137 Delivery to Enhance Necroptosis in Prostate Cancer. Advanced healthcare materials, e71387.

Chen Y, et al. (2025) ALKBH5-IGF2BP2 axis mediates prostate cancer progression and docetaxel resistance via m6A-stabilized CLSPN RNA. iScience, 28(10), 113520.

Sheng H, et al. (2025) KBTBD11 loss promotes AKT hyperactivation and therapeutic vulnerability in prostate cancer. Oncogene.

Hofstad M, et al. (2025) Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer. Oncogene, 44(22), 1746.

Guo C, et al. (2025) ADT increases prostate cancer cell invasion via altering AR/SALL4/SOX2-OCT4 stem cell signaling. Cell biology and toxicology, 41(1), 107.

Hawsawi O, et al. (2025) Mitochondrial uncouplers inhibit oncogenic E2F1 activity and prostate cancer growth. Cell reports. Medicine, 6(1), 101890.

Huang Y, et al. (2025) Development and validation of a kinase-related gene signature as a novel diagnostic and prognostic model for prostate cancer. Biochimica et biophysica acta. Molecular basis of disease, 1871(4), 167722.

Hirani R, et al. (2025) BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways. Cell reports, 44(6), 115779.

Baker MJ, et al. (2025) VAV2 Drives EGFR-Mediated Rac1 Responses in Prostate Cancer. Molecular cancer research : MCR, 23(8), 684.

Labaf M, et al. (2025) Heterogeneous Responses to High-Dose Testosterone in Castration-Resistant Prostate Cancer Tumors with Mixed Rb-Proficient and Rb-Deficient Cells. Molecular cancer therapeutics, 24(5), 772.

Ye Q, et al. (2025) A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition. Cancer research, 85(18), 3490.